{
  "guideline": {
    "id": "PA166192321",
    "name": "Annotation of CPIC Guideline for piroxicam and CYP2C9",
    "source": "CPIC",
    "version": 8,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166192321",
    "relatedChemicals": [
      {
        "id": "PA450985",
        "name": "piroxicam",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298444",
      "name": "Recommendation PA166298444",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450985",
          "name": "piroxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061046,
        "html": "<p>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.</p>\n"
      },
      "implications": [
        "CYP2C9: Mildly reduced metabolism"
      ],
      "lookupKey": {
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298448",
      "name": "Recommendation PA166298448",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450985",
          "name": "piroxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061050,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C9: n/a"
      ],
      "lookupKey": {
        "CYP2C9": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298445",
      "name": "Recommendation PA166298445",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450985",
          "name": "piroxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061047,
        "html": "<p>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</p>\n"
      },
      "implications": [
        "CYP2C9: Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities"
      ],
      "lookupKey": {
        "CYP2C9": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298446",
      "name": "Recommendation PA166298446",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450985",
          "name": "piroxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061048,
        "html": "<p>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</p>\n"
      },
      "implications": [
        "CYP2C9: Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
      ],
      "lookupKey": {
        "CYP2C9": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298447",
      "name": "Recommendation PA166298447",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450985",
          "name": "piroxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061049,
        "html": "<p>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</p>\n"
      },
      "implications": [
        "CYP2C9: Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
      ],
      "lookupKey": {
        "CYP2C9": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298443",
      "name": "Recommendation PA166298443",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450985",
          "name": "piroxicam",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061045,
        "html": "<p>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</p>\n"
      },
      "implications": [
        "CYP2C9: Normal metabolism"
      ],
      "lookupKey": {
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "32189324",
      "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.",
      "authors": [
        "Theken Katherine N",
        "Lee Craig R",
        "Gong Li",
        "Caudle Kelly E",
        "Formea Christine M",
        "Gaedigk Andrea",
        "Klein Teri E",
        "Agúndez José A G",
        "Grosser Tilo"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2020
    }
  ],
  "version": "2024-03-25-16-13"
}